| Rapport Therapeutics, Inc. |
Chief Executive Officer, Director |
Common Stock |
574K |
$14.6M |
$25.43 |
Nov 17, 2025 |
Direct |
| Rapport Therapeutics, Inc. |
Chief Executive Officer, Director |
Common Stock |
81.7K |
$2.16M |
$26.43 |
Nov 17, 2025 |
By Ceesay Family Irrevocable Trust |
| Cerevel Therapeutics Holdings, Inc. |
President |
Restricted Stock Units |
29.1K |
$1.23M |
$42.24 |
Feb 6, 2023 |
Direct |
| Rapport Therapeutics, Inc. |
Chief Executive Officer, Director |
Common Stock |
36K |
$915K |
$25.44 |
Nov 17, 2025 |
By Dorothy Ceesay Irrevocable Trust |
| Pacira BioSciences, Inc. |
Director |
Stock Option (Right to Buy) |
11.3K |
$324K |
$26.59 |
Jun 11, 2025 |
Direct |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. |
Director |
Stock Options (Right to Buy) |
2.08K |
$281K |
$135.04 |
Jun 2, 2025 |
Direct |
| Pacira BioSciences, Inc. |
Director |
Common Stock |
9.04K |
$246K |
$27.19 |
Sep 4, 2025 |
Direct |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. |
Director |
Common Stock |
946 |
$128K |
$135.04 |
Jun 2, 2025 |
Direct |
| Rapport Therapeutics, Inc. |
Chief Executive Officer, Director |
Stock Option (Right to Buy) |
428K |
|
|
Feb 3, 2025 |
Direct |
| Cerevel Therapeutics Holdings, Inc. |
President |
Stock Option (Right to Buy) |
114K |
|
|
Feb 6, 2023 |
Direct |
| Cerevel Therapeutics Holdings, Inc. |
President |
Common Stock |
0 |
|
$42.24 |
Sep 8, 2022 |
Direct |